Minerva Neurosciences, Inc (NERV) Dividend History

Company News

• Schizophrenia Market to Witness Significant Growth by 2034 Across 7MM as New Therapies Enter Late-Stage Trials | DelveInsight

  The schizophrenia market is expected to grow significantly by 2034, driven by rising disease prevalence, expanding approved therapies, and the anticipated launch of new treatments such as Olanzapine LAI, Iclepertin, Ulotaront, and Brilaroxazine.

  GlobeNewswire Inc.

  Featured Companies: RVPH
• Cartesian (RNAC) MG Study Meets Goals, Stock Down on Other Updates - Zacks Investment Research

  Cartesian Therapeutics announced positive top-line results from its mid-stage study evaluating lead candidate Descartes-08 in patients with generalized myasthenia gravis. The study achieved its primary endpoint, with 71% of MG patients treated with Descartes-08 showing significant improvements in MG Composite score compared to 25% with placebo.

  Zacks Investment Research

  Featured Companies: ALXO RNAC
• Dow Dips Over 100 Points; J.M. Smucker Posts Upbeat Earnings

  U.S. stocks traded mixed toward the end of trading, with the Dow Jones index falling more than 100 points on Tuesday. The Dow traded down 0.35% to 38,932.26 while the NASDAQ rose 0.28% to 16,021.41. The S&P 500 also rose, gaining, 0.04% to 5,071.40. Check This Out: Wall Street's Most Accurate Analysts' Views On 3 Risk Off Stocks With Over 5% Dividend Yields   Leading and Lagging Sectors   Utilities shares rose by 1.2% on Tuesday. In trading on Tuesday, energy shares fell by 0.4%.   Top Headline   The J.M. Smucker Company (NYSE: SJM) posted better-than-expected earnings for its fourth quarter on Tuesday. The company reported third-quarter adjusted earnings per share of $2.48, beating the analyst consensus of $2.27. J.M. Smucker registered quarterly revenues of $2.229 billion, marginally beating the consensus estimate of $2.220 billion.   Equities Trading UP   Janux Therapeutics, Inc. (NASDAQ: JANX) shares shot up 191% to $44.00 after the company announced updated clinical data for both of its clinical programs. Shares of Hims & Hers Health, Inc. (NYSE: HIMS) got a boost, surging 32% to $13.50 after the company reported better-than-expected fourth-quarter financial results and issued strong guidance. Viking Therapeutics, Inc. ...

  Benzinga

  Featured Companies: HIMS JANX NRXP SJM VKTX
• Hot Penny Stocks To Buy For Under $1 Right Now

  Penny stocks under $1 to watch this week. The post Hot Penny Stocks To Buy For Under $1 Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

  PennyStocks

  Featured Companies: MULN PSTV TMC